Phase I Trial of Silymarin for Chronic Liver Diseases
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of different dosages of
silymarin on subjects with Hepatitis C or Non-Alcoholic Fatty Liver Disease.
Phase:
Phase 1
Details
Lead Sponsor:
National Center for Complementary and Integrative Health (NCCIH)
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)